Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:MXCT NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$51.40-1.2%$51.51$37.02▼$78.48$4.96B1.741.84 million shs556,780 shsMXCTMaxCyte$1.19-3.7%$0.88$0.64▼$2.40$126.94M1.481.07 million shs351,599 shsVRTXVertex Pharmaceuticals$426.88+0.4%$438.67$362.50▼$507.92$108.34B0.31.37 million shs599,254 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-4.00%+0.83%+0.76%-13.30%+40.78%MXCTMaxCyte+0.82%+23.00%+39.77%+60.28%-45.58%VRTXVertex Pharmaceuticals-3.04%-2.49%+0.28%-11.05%-4.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$51.40-1.2%$51.51$37.02▼$78.48$4.96B1.741.84 million shs556,780 shsMXCTMaxCyte$1.19-3.7%$0.88$0.64▼$2.40$126.94M1.481.07 million shs351,599 shsVRTXVertex Pharmaceuticals$426.88+0.4%$438.67$362.50▼$507.92$108.34B0.31.37 million shs599,254 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-4.00%+0.83%+0.76%-13.30%+40.78%MXCTMaxCyte+0.82%+23.00%+39.77%+60.28%-45.58%VRTXVertex Pharmaceuticals-3.04%-2.49%+0.28%-11.05%-4.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$65.4727.37% UpsideMXCTMaxCyte 2.20Hold$5.50364.14% UpsideVRTXVertex Pharmaceuticals 2.88Moderate Buy$555.9130.23% UpsideCurrent Analyst Ratings BreakdownLatest MXCT, VRTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026VRTXVertex Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$542.005/18/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.005/11/2026CRSPCRISPR Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$76.005/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/6/2026VRTXVertex Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$607.00 ➝ $615.005/5/2026VRTXVertex Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$612.00 ➝ $616.005/5/2026VRTXVertex Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$541.00 ➝ $543.005/5/2026VRTXVertex Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$577.00 ➝ $572.005/5/2026VRTXVertex Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$437.00 ➝ $436.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,412.40N/AN/A$20.17 per share2.55MXCTMaxCyte$32.29M3.93N/AN/A$1.61 per share0.74VRTXVertex Pharmaceuticals$12.00B9.03$17.12 per share24.94$73.57 per share5.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)MXCTMaxCyte-$44.63M-$0.37N/AN/AN/A-121.16%-20.03%-17.14%8/12/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8625.3222.541.8835.51%23.86%17.13%8/3/2026 (Estimated)Latest MXCT, VRTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026MXCTMaxCyte-$0.10-$0.04+$0.06-$0.04$7.28 million$6.22 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/24/2026Q4 2025MXCTMaxCyte-$0.08-$0.06+$0.02-$0.09$9.16 million$6.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9717.96MXCTMaxCyteN/A12.0411.29VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%MXCTMaxCyte68.81%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%MXCTMaxCyte4.10%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million92.50 millionOptionableMXCTMaxCyte80107.12 million102.73 millionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableMXCT, VRTX, and CRSP HeadlinesRecent News About These CompaniesVertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?43 minutes ago | zacks.comShepherd Street Advisors LLC Buys Shares of 2,995 Vertex Pharmaceuticals Incorporated $VRTXJune 3 at 6:44 AM | marketbeat.comVertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?June 3 at 1:51 AM | finance.yahoo.comIs Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation?June 2 at 7:26 PM | finance.yahoo.comAnalyst Report: Vertex Pharmaceuticals IncJune 2 at 3:11 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated: Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX, a First-in-Class Non-Opioid Treatment for Adults ...June 2 at 2:25 PM | finanznachrichten.deShould FDA’s IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticals’ (VRTX) Investment Narrative?June 2 at 2:25 PM | finance.yahoo.comGot $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely MispricingJune 2 at 12:11 PM | 247wallst.comFDA Accepts Vertex's BLA for Povetacicept in IgA NephropathyJune 2 at 12:10 PM | zacks.comGot $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely MispricingJune 2 at 12:02 PM | 247wallst.comNatixis Advisors LLC Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJune 2 at 7:25 AM | marketbeat.comGW Henssler & Associates Ltd. Trims Stake in Vertex Pharmaceuticals Incorporated $VRTXJune 2 at 6:45 AM | marketbeat.comVertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?June 1 at 2:10 PM | barchart.comVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA NephropathyJune 1 at 12:09 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowJune 1 at 12:09 PM | finance.yahoo.comVertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?June 1 at 12:09 PM | finance.yahoo.comVertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?June 1 at 10:25 AM | zacks.comVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowJune 1 at 10:01 AM | zacks.comWaterloo Capital L.P. Invests $1.78 Million in Vertex Pharmaceuticals Incorporated $VRTXJune 1 at 7:04 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Bought by Nomura Asset Management Co. Ltd.June 1 at 5:57 AM | marketbeat.comMUFG Securities EMEA plc Purchases 5,494 Shares of Vertex Pharmaceuticals Incorporated $VRTXJune 1 at 5:49 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMXCT, VRTX, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$51.40 -0.62 (-1.19%) As of 01:03 PM EasternCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.MaxCyte NASDAQ:MXCT$1.18 -0.05 (-3.66%) As of 01:02 PM EasternMaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Vertex Pharmaceuticals NASDAQ:VRTX$426.88 +1.79 (+0.42%) As of 01:03 PM EasternVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today" Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
